Moreover, from the long follow-up period we highlighted an increasing difference in the probability of death between the patients belonging to the group with a high tumor expression of IDO2 and those belonging to the low expression group (28% compared to near 12% within 60 months). Here, IDO2 is linked to neoplasm.